- 收听数
- 0
- 性别
- 保密
- 听众数
- 20
- 最后登录
- 2024-9-27
- QQ
- UID
- 14830
- 阅读权限
- 20
- 帖子
- 320
- 精华
- 0
- 在线时间
- 91 小时
- 注册时间
- 2015-9-23
- 科研币
- 5
- 速递币
- 743
- 娱乐币
- 3834
- 文献值
- 13
- 资源值
- 0
- 贡献值
- 0
|
5速递币
题名 | Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group | 作者 | de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R | 链接 | http://www.ncbi.nlm.nih.gov/pubmed/9519356 |
|
|